199 related articles for article (PubMed ID: 21680240)
21. Axonal loss influences the response to rituximab treatment in neuropathy associated with IgM monoclonal gammopathy with anti-myelin-associated glycoprotein antibody.
Kawagashira Y; Koike H; Ohyama K; Hashimoto R; Iijima M; Adachi H; Katsuno M; Chapman M; Lunn M; Sobue G
J Neurol Sci; 2015 Jan; 348(1-2):67-73. PubMed ID: 25467141
[TBL] [Abstract][Full Text] [Related]
22. Antibodies to myelin-associated glycoprotein (anti-Mag) in IgM amyloidosis may influence expression of neuropathy in rare patients.
Garces-Sanchez M; Dyck PJ; Kyle RA; Zeldenrust S; Wu Y; Ladha SS; Klein CJ
Muscle Nerve; 2008 Apr; 37(4):490-5. PubMed ID: 18236455
[TBL] [Abstract][Full Text] [Related]
23. Anti-myelin-associated glycoprotein neuropathy.
Steck AJ; Stalder AK; Renaud S
Curr Opin Neurol; 2006 Oct; 19(5):458-63. PubMed ID: 16969155
[TBL] [Abstract][Full Text] [Related]
24. Heterogeneity of Polyneuropathy Associated with Anti-MAG Antibodies.
Magy L; Kaboré R; Mathis S; Lebeau P; Ghorab K; Caudie C; Vallat JM
J Immunol Res; 2015; 2015():450391. PubMed ID: 26065001
[TBL] [Abstract][Full Text] [Related]
25. Outcomes after single-cycle rituximab monotherapy in patients with anti-MAG polyneuropathy: A bi-center experience with an average follow-up of 11 years.
Benedetti L; Garnero M; Demichelis C; Grandis M; Briani C; Beltramini S; Bellucci M; Prada V; Massa F; Gastaldi M; Schenone A; Franciotta D
J Neuroimmunol; 2019 Dec; 337():577081. PubMed ID: 31677562
[TBL] [Abstract][Full Text] [Related]
26. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy.
Léger JM; Viala K; Nicolas G; Créange A; Vallat JM; Pouget J; Clavelou P; Vial C; Steck A; Musset L; Marin B;
Neurology; 2013 Jun; 80(24):2217-25. PubMed ID: 23667063
[TBL] [Abstract][Full Text] [Related]
27. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial.
Gorson KC; Natarajan N; Ropper AH; Weinstein R
Muscle Nerve; 2007 Jan; 35(1):66-9. PubMed ID: 16967492
[TBL] [Abstract][Full Text] [Related]
28. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.
Teng YK; Levarht EW; Hashemi M; Bajema IM; Toes RE; Huizinga TW; van Laar JM
Arthritis Rheum; 2007 Dec; 56(12):3909-18. PubMed ID: 18050222
[TBL] [Abstract][Full Text] [Related]
29. Predictive factors of efficacy of rituximab in patients with anti-MAG neuropathy.
Gazzola S; Delmont E; Franques J; Boucraut J; Salort-Campana E; Verschueren A; Sagui E; Hubert AM; Pouget J; Attarian S
J Neurol Sci; 2017 Jun; 377():144-148. PubMed ID: 28477685
[TBL] [Abstract][Full Text] [Related]
30. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
[TBL] [Abstract][Full Text] [Related]
31. Differential diagnosis of chronic dysimmune demyelinating polyneuropathies with and without anti-MAG antibodies.
Isoardo G; Migliaretti G; Ciaramitaro P; Rota E; Poglio F; Tavella A; Paolasso I; Cavallo F; Bergamasco B; Cocito D
Muscle Nerve; 2005 Jan; 31(1):52-8. PubMed ID: 15536620
[TBL] [Abstract][Full Text] [Related]
32. [Experience with rituximab treatment (monoclonal antibodies to B-lymphocyte CD20 receptors) of Wegener's granulomatosis patients with renal impairment].
Novikov PI; Krivosheev OG; Semenkova EN
Ter Arkh; 2011; 83(11):70-6. PubMed ID: 22312891
[TBL] [Abstract][Full Text] [Related]
33. Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features.
Svahn J; Petiot P; Antoine JC; Vial C; Delmont E; Viala K; Steck AJ; Magot A; Cauquil C; Zarea A; Echaniz-Laguna A; Iancu Ferfoglia R; Gueguen A; Magy L; Léger JM; Kuntzer T; Ferraud K; Lacour A; Camdessanché JP;
J Neurol Neurosurg Psychiatry; 2018 May; 89(5):499-505. PubMed ID: 29070644
[TBL] [Abstract][Full Text] [Related]
34. Intermittent cyclophosphamide with prednisone versus placebo for polyneuropathy with IgM monoclonal gammopathy.
Niermeijer JM; Eurelings M; van der Linden MW; Lokhorst HM; Franssen H; Fischer K; Teunissen LL; van den Berg LH; Schobben F; Wokke JH; Notermans NC
Neurology; 2007 Jul; 69(1):50-9. PubMed ID: 17606880
[TBL] [Abstract][Full Text] [Related]
35. Polyneuropathy associated with IgM vs IgG monoclonal gammopathy: comparison between clinical and electrophysiological findings.
Vrethem M; Reiser N; Lauermann C; Svanborg E
Acta Neurol Scand; 2010 Jul; 122(1):52-7. PubMed ID: 20003083
[TBL] [Abstract][Full Text] [Related]
36. Correlation of Changes in Gait Parameters, With Phenotype, Outcome Measures, and Electrodiagnostic Abnormalities in a Patient With Anti-MAG Neuropathy After Exacerbation and Improvement.
Vo ML; Martin P; Latov N
J Clin Neuromuscul Dis; 2015 Sep; 17(1):22-6. PubMed ID: 26301376
[TBL] [Abstract][Full Text] [Related]
37. Rituximab for polyneuropathy with IgM monoclonal gammopathy.
Niermeijer JM; Eurelings M; Lokhorst HL; van der Pol WL; Franssen H; Wokke JH; Notermans NC
J Neurol Neurosurg Psychiatry; 2009 Sep; 80(9):1036-9. PubMed ID: 19684235
[TBL] [Abstract][Full Text] [Related]
38. Treatment with rituximab in patients with polyneuropathy with anti-MAG antibodies.
Delmont E; Jeandel PY; Benaïm C; Rosenthal E; Fuzibet JG; Desnuelle C
J Neurol; 2011 Sep; 258(9):1717-9. PubMed ID: 21437663
[No Abstract] [Full Text] [Related]
39. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome.
Pranzatelli MR; Tate ED; Travelstead AL; Barbosa J; Bergamini RA; Civitello L; Franz DN; Greffe BS; Hanson RD; Hurwitz CA; Kalinyak KA; Kelfer H; Khakoo Y; Mantovani JF; Nicholson SH; Sanders JM; Wegner S
J Pediatr Hematol Oncol; 2006 Sep; 28(9):585-93. PubMed ID: 17006265
[TBL] [Abstract][Full Text] [Related]
40. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris.
El Tal AK; Posner MR; Spigelman Z; Ahmed AR
J Am Acad Dermatol; 2006 Sep; 55(3):449-59. PubMed ID: 16908351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
